news
High doses of favipiravir combat SARS-CoV-2 in hamsters
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
List view / Grid view
In Vivo
news
CRISPR used to eliminate cancers caused by fusion genes
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
news
Small molecules to reduce cellular stress identified by HTS
Scientists used high throughput screening (HTS) to identify molecules that protect against cellular stress in murine skin cells.
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-750x500.jpg)
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-e1601552379990.jpg)
news
Identifying radioresistance drivers in glioblastoma multiforme
According to researchers, Rab27b and epiregulin contribute to the development of radioresistance and could be targeted to improve glioblastoma patient survival.
news
Stem cell therapy repairs Parkinson’s degeneration in mice
Researchers demonstrate that transplanting dopaminergic neurons grown from stem cells into the brains of mice improved motor skills.
news
Novel compounds show efficacy against C. diff
Researchers have developed two novel trifluoromethylthio compounds which showed potent activity in protecting mice from Clostridioides difficile (C. diff) infection.
news
Experimental antiviral AR-12 could be a promising COVID-19 treatment
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
article
Developing IL-15 superagonists for cancer therapy
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
news
Lethal poxviruses could be rendered harmless with single gene removal
Researchers report that removing the vSLFN gene from the ectromelia virus (ECTV) caused a potent immune response which protected animal models.
news
4-PBA could prevent cytokine storm in severe COVID-19
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
news
A novel drug target for viral encephalitis therapies
Researchers showed CXCL1 signalling to neutrophils drove brain inflammation in herpes simplex virus (HSV) encephalitis and blocking the protein resulted in less severe disease.
news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Defusing antibody neutralisers in AAV gene therapy
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
news
Novel lysin-based antibacterial agent could help combat MRSA
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.